Volume 6, Number 1 (19 2006)                   ijdld 2006, 6(1): 91-99 | Back to browse issues page


XML Persian Abstract Print


Download citation:
BibTeX | RIS | EndNote | Medlars | ProCite | Reference Manager | RefWorks
Send citation to:

Sardar M A, Shamsian A A, Taghavi M. THE INTERACTION EFFECT OF GLIBENCLAMIDE AND AEROBIC TRAINING ON C-PEPTIDE , INSULIN AND INSULIN RESISTANCE IN TYPE 2 DIABETIC PATIENTS. ijdld. 2006; 6 (1) :91-99
URL: http://ijdld.tums.ac.ir/article-1-342-en.html

Abstract:   (4996 Views)
Background: Combination of physical activity and pharmacotherapy in diabetes may augment the effects of the drug and may allow lower doses of medication that can minimize the side effects. The goal of the study was to determine the effectiveness of aerobic training and Glibenclamide combination in type 2 diabetes.
Methods: A total of 28 men with type 2 diabetes were divided to 3 groups randomly: Glibenclamide (5 mg daily) only, Glibenclamide (5 mg daily) plus aerobic training, Glibenclamide (2.5 mg daily) plus aerobic training. Aerobic training protocol was performed for 12 week, 3 days (session) a week, 45 minutes in a session (ergo cycle program at 60-70 % heart rate reserve). Fasting glucose, HbA1c, fasting insulin, c-peptide, and insulin resistance were measured at pre, mid and post treatment periods. Analysis of Variance test (ANOVA) were used to evaluate data.
Results:
HbA1c significantly decreased and c-peptide significantly increased in three groups (P<0.05).There were also no between-group differences for c-peptide and HbA1c (P>0.05). Fasting insulin concentration did not alter in three groups, however, insulin resistance decreased ( no significant ) after 12 weeks.
Conclusion: In type 2 diabetic patients, Glibenclamide treatment alone or combination of aerobic training and Glibenclamide treatment, was effective in improving glycemic control in patients with type 2 diabetes .As a result, in patients with type 2 diabetes, the addition of aerobic training to Glibencelamide treatment allow lower doses of Glibenclamide to be used without impairment in glycemic control.
Full-Text [PDF 234 kb]   (946 Downloads)    
Type of Study: Research | Subject: General
Received: 2006/07/11 | Accepted: 2007/01/23 | Published: 2013/10/3

Add your comments about this article : Your username or email:
Write the security code in the box

© 2017 All Rights Reserved | Iranian Journal of Diabetes and Metabolism

Designed & Developed by : Yektaweb